vs

Side-by-side financial comparison of NewtekOne, Inc. (NEWT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

NewtekOne, Inc. is the larger business by last-quarter revenue ($73.3M vs $37.2M, roughly 2.0× Organogenesis Holdings Inc.). On growth, NewtekOne, Inc. posted the faster year-over-year revenue change (-2.7% vs -57.1%). Over the past eight quarters, NewtekOne, Inc.'s revenue compounded faster (12.2% CAGR vs -46.5%).

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

NEWT vs ORGO — Head-to-Head

Bigger by revenue
NEWT
NEWT
2.0× larger
NEWT
$73.3M
$37.2M
ORGO
Growing faster (revenue YoY)
NEWT
NEWT
+54.4% gap
NEWT
-2.7%
-57.1%
ORGO
Faster 2-yr revenue CAGR
NEWT
NEWT
Annualised
NEWT
12.2%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NEWT
NEWT
ORGO
ORGO
Revenue
$73.3M
$37.2M
Net Profit
$19.5M
Gross Margin
30.8%
Operating Margin
-185.1%
Net Margin
111.8%
Revenue YoY
-2.7%
-57.1%
Net Profit YoY
6.6%
EPS (diluted)
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEWT
NEWT
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$73.3M
$225.6M
Q3 25
$74.9M
$150.9M
Q2 25
$70.2M
$101.0M
Q1 25
$66.3M
$86.7M
Q4 24
$75.4M
$126.7M
Q3 24
$62.8M
$115.2M
Q2 24
$61.1M
$130.2M
Net Profit
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
$19.5M
$43.7M
Q3 25
$17.9M
$21.6M
Q2 25
$13.7M
$-9.4M
Q1 25
$9.4M
$-18.8M
Q4 24
$18.3M
$7.7M
Q3 24
$11.9M
$12.3M
Q2 24
$10.9M
$-17.0M
Gross Margin
NEWT
NEWT
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
NEWT
NEWT
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Net Margin
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
111.8%
19.4%
Q3 25
23.9%
14.3%
Q2 25
19.5%
-9.3%
Q1 25
14.1%
-21.7%
Q4 24
24.3%
6.1%
Q3 24
19.0%
10.7%
Q2 24
17.9%
-13.1%
EPS (diluted)
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
$0.64
$0.31
Q3 25
$0.67
$0.11
Q2 25
$0.52
$-0.10
Q1 25
$0.35
$-0.17
Q4 24
$0.70
$0.05
Q3 24
$0.45
$0.09
Q2 24
$0.43
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEWT
NEWT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$91.4M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$397.6M
Total Assets
$2.7B
$520.0M
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEWT
NEWT
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Total Debt
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
$62.3M
Q2 24
$652.0M
$63.8M
Stockholders' Equity
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
$397.6M
$300.1M
Q3 25
$386.7M
$255.1M
Q2 25
$312.2M
$233.2M
Q1 25
$302.3M
$242.9M
Q4 24
$296.3M
$262.9M
Q3 24
$281.8M
$278.5M
Q2 24
$274.0M
$263.5M
Total Assets
NEWT
NEWT
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$2.7B
$598.7M
Q3 25
$2.4B
$509.8M
Q2 25
$2.1B
$461.1M
Q1 25
$2.1B
$467.4M
Q4 24
$2.1B
$497.9M
Q3 24
$1.7B
$446.3M
Q2 24
$1.6B
$443.2M
Debt / Equity
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
0.22×
Q2 24
2.38×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEWT
NEWT
ORGO
ORGO
Operating Cash FlowLast quarter
$-579.2M
Free Cash FlowOCF − Capex
$-579.3M
FCF MarginFCF / Revenue
-790.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
$-579.2M
$39.4M
Q3 25
$-167.3M
$3.1M
Q2 25
$-199.8M
$-32.9M
Q1 25
$-60.7M
$-19.9M
Q4 24
$-153.0M
$10.9M
Q3 24
$-25.7M
$8.7M
Q2 24
$2.9M
$4.7M
Free Cash Flow
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
$-579.3M
$34.8M
Q3 25
$-167.3M
$844.0K
Q2 25
$-199.9M
$-36.5M
Q1 25
$-60.7M
$-23.6M
Q4 24
$-153.5M
$7.6M
Q3 24
$-25.9M
$6.1M
Q2 24
$2.9M
$2.9M
FCF Margin
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
-790.0%
15.4%
Q3 25
-223.3%
0.6%
Q2 25
-284.7%
-36.1%
Q1 25
-91.6%
-27.2%
Q4 24
-203.6%
6.0%
Q3 24
-41.2%
5.3%
Q2 24
4.7%
2.2%
Capex Intensity
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
0.1%
2.1%
Q3 25
0.0%
1.5%
Q2 25
0.1%
3.6%
Q1 25
0.1%
4.2%
Q4 24
0.6%
2.7%
Q3 24
0.4%
2.2%
Q2 24
0.1%
1.4%
Cash Conversion
NEWT
NEWT
ORGO
ORGO
Q1 26
Q4 25
-29.64×
0.90×
Q3 25
-9.35×
0.14×
Q2 25
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
1.43×
Q3 24
-2.15×
0.71×
Q2 24
0.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons